Antimycotic Azoles (all routes except local only) updated on 01-29-2025

Diaphragmatic hernia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17734
R74880		 Howley - Fluconazole, 2016 Diaphragmatic hernia 1st trimester case control unexposed (general population or NOS) Adjustment: No Fluconazole not specified or mixed dose 4.44 [0.89;22.01] C 2/8   872/12,478 874 8
ref
S17735
R74925		 Molgaard-Nielsen - Fluconazole, 2013 Diaphragmatic hernia 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Fluconazole not specified or mixed dose 1.36 [0.34;5.49] 2/7,352   202/968,236 204 7,352
ref
S17725
R74799		 Carter - Miconazole, 2008 Diaphragmatic hernia 1st trimester case control unexposed (general population or NOS) Adjustment: No 0.89 [0.21;3.70] C 2/41   273/5,008 275 41
ref
Total 3 studies 1.64 [0.67;4.04] 1,353 7,401
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Howley - Fluconazole, 2016Howley - Fluconazole, 2016 4.44[0.89; 22.01]874828%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Molgaard-Nielsen - Fluconazole, 2013Molgaard-Nielsen - Fluconazole, 2013 1.36[0.34; 5.49]2047,35237%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Carter - Miconazole, 2008Carter - Miconazole, 2008 0.89[0.21; 3.70]2754135%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 11% 1.64[0.67; 4.04]1,3537,4010.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.36[0.34; 5.46]2047,352 -NAMolgaard-Nielsen - Fluconazole, 2013 1 case control studiescase control studies 1.90[0.39; 9.17]1,1494954%NAHowley - Fluconazole, 2016 Carter - Miconazole, 2008 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.64[0.67; 4.04]1,3537,40111%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 Carter - Miconazole, 2008 3 Tags Adjustment   - No  - No 1.90[0.39; 9.17]1,1494954%NAHowley - Fluconazole, 2016 Carter - Miconazole, 2008 2   - Yes  - Yes 1.36[0.34; 5.46]2047,352 -NAMolgaard-Nielsen - Fluconazole, 2013 1 Fluconazole not specified or mixed doseFluconazole not specified or mixed dose 2.29[0.73; 7.24]1,0787,36016%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 2 All studiesAll studies 1.64[0.67; 4.04]1,3537,40111%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 Carter - Miconazole, 2008 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.64[0.67; 4.04]1,3537,40111%NAHowley - Fluconazole, 2016 Molgaard-Nielsen - Fluconazole, 2013 Carter - Miconazole, 2008 30.510.01.0